Raymond James Financial Inc. Acquires Shares of 371,996 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Raymond James Financial Inc. bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 371,996 shares of the company's stock, valued at approximately $2,946,000. Raymond James Financial Inc. owned approximately 0.12% of Amneal Pharmaceuticals at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Quest Partners LLC purchased a new stake in shares of Amneal Pharmaceuticals in the third quarter worth $84,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $81,000. Janney Montgomery Scott LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $121,000. Quadrature Capital Ltd purchased a new position in shares of Amneal Pharmaceuticals during the third quarter worth about $169,000. Finally, Entropy Technologies LP bought a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $259,000. 31.82% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on AMRX. StockNews.com lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Finally, Barclays upped their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $10.80.

Insider Activity

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This represents a 9.33 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $8.14, for a total transaction of $651,200.00. Following the completion of the transaction, the director now owns 1,888,886 shares in the company, valued at $15,375,532.04. The trade was a 4.06 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,240,000 shares of company stock valued at $43,754,000. Insiders own 17.46% of the company's stock.

Amneal Pharmaceuticals Trading Down 0.7 %

Shares of AMRX traded down $0.06 during mid-day trading on Wednesday, reaching $8.17. The company's stock had a trading volume of 1,468,765 shares, compared to its average volume of 1,380,546. Amneal Pharmaceuticals, Inc. has a 52 week low of $5.18 and a 52 week high of $9.48. The stock has a market cap of $2.53 billion, a PE ratio of -12.01 and a beta of 1.06. The company's fifty day moving average price is $8.40 and its two-hundred day moving average price is $8.37.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same period in the prior year, the firm earned $0.14 earnings per share. Research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.